Bibliotecas PUC-SP - Busca Integrada

Acute Myeloid Leukemia: Focus on novel Therapeutic Strategies

von Tara L. Lin, M. Yair Levy
Veröffentlicht in Clinical Medicine Insights: Oncology (2012-01-01)

Acute Myeloid Leukemia: Focus on Novel Therapeutic Strategies

von Tara L. Lin, M. Yair Levy
Veröffentlicht in Clinical Medicine Insights: Oncology (2012-05-01)

High-Risk Microgranular Acute Promyelocytic Leukemia with a Five-Way Complex Translocation Involving PML-RARA

von Benjamin Powers, Diane Persons, Deepthi Rao, Janet Woodroof, Tara L. Lin
Veröffentlicht in Case Reports in Hematology (2015-01-01)

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysi...

von Jorge E. Cortes, Tara L. Lin, Kobby Asubonteng, Stefan Faderl, Jeffrey E. Lancet, Thomas Prebet
Veröffentlicht in Journal of Hematology & Oncology (2022-10-01)

Bendamustine Associated with Irreversible Ascending Paralysis

von Ashraf Alhafez, Omar S. Aljitawi, Tara L. Lin, Siddhartha Ganguly, Sunil Abhyankar, Joseph P. McGuirk
Veröffentlicht in Case Reports in Hematology (2013-01-01)

Quality-adjusted Time Without Symptoms of disease or Toxicity (Q-TWiST) analysis of CPX-351 versus 7 + 3 in older adults with newly diagnosed high-risk/secondary AML

von Jorge E. Cortes, Tara L. Lin, Geoffrey L. Uy, Robert J. Ryan, Stefan Faderl, Jeffrey E. Lancet
Veröffentlicht in Journal of Hematology & Oncology (2021-07-01)

A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia

von Fatih M. Uckun, Christopher R. Cogle, Tara L. Lin, Sanjive Qazi, Vuong N. Trieu, Gary Schiller, Justin M. Watts
Veröffentlicht in Cancers (2019-12-01)

P516: CARDIOTOXICITY OF CPX-351 VS 7 + 3 IN PATIENTS WITH UNTREATED HIGH-RISK ACUTE MYELOID LEUKEMIA

von Joshua D. Mitchell, Michael Pfeiffer, John Boehmer, John Gorcsan, Nalina Dronamraju, Stefan Faderl, Tara L. Lin, Geoffrey L. Uy, Jeffrey Lancet, Jorge Cortes
Veröffentlicht in HemaSphere (2023-08-01)

Risk, Characteristics and Biomarkers of Cytokine Release Syndrome in Patients with Relapsed/Refractory AML or MDS Treated with CD3xCD123 Bispecific Antibody APVO436

von Fatih M. Uckun, Justin Watts, Alice S. Mims, Prapti Patel, Eunice Wang, Paul J. Shami, Elizabeth Cull, Cynthia Lee, Christopher R. Cogle, Tara L. Lin
Veröffentlicht in Cancers (2021-10-01)

A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

von Fatih M. Uckun, Tara L. Lin, Alice S. Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul J. Shami, Elizabeth Cull, Christopher R. Cogle, Justin Watts
Veröffentlicht in Cancers (2021-08-01)

Post-hoc Analysis of Pharmacodynamics and Single-Agent Activity of CD3xCD123 Bispecific Antibody APVO436 in Relapsed/Refractory AML and MDS Resistant to HMA or Venetoclax Plus HMA

von Justin Watts, Tara L. Lin, Alice Mims, Prapti Patel, Cynthia Lee, Anoush Shahidzadeh, Paul Shami, Elizabeth Cull, Christopher R. Cogle, Eunice Wang, Fatih M. Uckun, Fatih M. Uckun
Veröffentlicht in Frontiers in Oncology (2022-01-01)

Using Bayesian hierarchical modeling for performance evaluation of clinical trial accrual for a cancer center

von Xiaosong Shi, Dinesh Pal Mudaranthakam, Jo A. Wick, David Streeter, Jeffrey A. Thompson, Natalie R. Streeter, Tara L. Lin, Joseph Hines, II, Matthew S. Mayo, Byron J. Gajewski
Veröffentlicht in Contemporary Clinical Trials Communications (2024-04-01)

P517: SURVIVAL OUTCOMES WITH CPX-351 VS 7 + 3 BY BASELINE BONE MARROW BLAST PERCENTAGE IN OLDER ADULTS WITH NEWLY DIAGNOSED HIGH-RISK OR SECONDARY ACUTE MYELOID LEUKEMIA: A 5-YEAR...

von Ellen Ritchie, Tara L. Lin, Laura F. Newell, Robert K. Stuart, Scott Solomon, Richard Stone, Gary Schiller, Matthew Wieduwilt, Eileen Amy Ryan, Nalina Dronamraju, Jeffrey Lancet, Jorge Cortes
Veröffentlicht in HemaSphere (2023-08-01)

Self-renewal of acute lymphocytic leukemia cells is limited by the Hedgehog pathway inhibitors cyclopamine and IPI-926.

von Tara L Lin, Qiuju H Wang, Patrick Brown, Craig Peacock, Akil A Merchant, Sarah Brennan, Evan Jones, Karen McGovern, D Neil Watkins, Kathleen M Sakamoto, William Matsui
Veröffentlicht in PLoS ONE (2010-12-01)

Lower-intensity CPX-351 plus venetoclax induction for adults with newly diagnosed AML unfit for intensive chemotherapy

von Geoffrey L. Uy, Vinod Pullarkat, Praneeth Baratam, Robert K. Stuart, Roland B. Walter, Eric S. Winer, Qi Wang, Stefan Faderl, Divya Chakravarthy, Diane Menno, Ronald S. Cheung, Tara L. Lin
Veröffentlicht in Blood Advances (2024-12-01)

V-FAST: a phase 1b master trial to investigate CPX-351 combined with targeted agents in adults with newly diagnosed AML

von Vinod A. Pullarkat, Mark Levis, James McCloskey, Gabriel N. Mannis, Stephen A. Strickland, Amir T. Fathi, Tara L. Lin, Vijaya R. Bhatt, Thuva Vanniyasingam, Divya Chakravarthy, Yana Lutska, Stefan Faderl, Ronald S. Cheung, Harry P. Erba
Veröffentlicht in Blood Neoplasia (2025-11-01)

Functional characterization of NPM1–TYK2 fusion oncogene

von Sudhakiranmayi Kuravi, Riley W. Baker, Muhammad Umair Mushtaq, Irfan Saadi, Tara L. Lin, Carolyn J. Vivian, Anusha Valluripalli, Sunil Abhyankar, Siddhartha Ganguly, Wei Cui, Kojo S. J. Elenitoba-Johnson, Danny R. Welch, Roy A. Jensen, Yogen Saunthararajah, Joseph P. McGuirk, Ramesh Balusu
Veröffentlicht in npj Precision Oncology (2022-01-01)

P512: A PHASE 1B/2 STUDY OF TP-0903 AND DECITABINE TARGETING MUTANT TP53 AND/OR COMPLEX KARYOTYPE IN PATIENTS WITH UNTREATED ACUTE MYELOID LEUKEMIA (AML) ≥ AGE 60 YEARS: FINAL RESU...

von Alice Mims, Ying Huang, Eric Eisenmann, Shelley Orwick, Daelynn Buelow, Ronan Swords, Joshua Zeidner, Matthew Foster, Tara L. Lin, Maria Baer, Yazan Madanat, Tibor Kovacsovics, Robert Redner, Zeina Al-Mansour, Mona Stefanos, Molly Martycz, Franchesca Druggan, Timothy Chen, Ashley Yocum, Uma Borate, Brian Druker, Amy Burd, Ross Levine, Sharyn Baker, John C. Byrd
Veröffentlicht in HemaSphere (2023-08-01)

A prospective biomarker analysis of alvocidib followed by cytarabine and mitoxantrone in MCL-1-dependent relapsed/refractory acute myeloid leukemia

von Joshua F. Zeidner, Tara L. Lin, Carlos E. Vigil, Gil Fine, M. Yair Levy, Aziz Nazha, Jordi Esteve, Daniel J. Lee, Karen Yee, Andrew Dalovisio, Eunice S. Wang, Juan M. Bergua Burgues, Jeffrey Schriber, Mark R. Litzow, Olga Frankfurt, Teresa Bernal Del Castillo, Vijaya Raj Bhatt, Bhavana Bhatnagar, Priyanka Mehta, Richard Dillon, Maria Vidriales Vicente, Stephen Anthony, David Bearss, Pau Montesinos, B. Douglas Smith
Veröffentlicht in Blood Cancer Journal (2021-10-01)

Randomized phase 2 study to assess the role of single-agent nivolumab to maintain remission in acute myeloid leukemia

von Athalia R. Pyzer, Laura W. Dillon, Elad Sharon, Theodore G. Karrison, Yuanyuan Zha, Noreen Fulton, Gege Gui, Georgia Andrew, Howard Streicher, Kendra Sweet, George Yaghmour, Jane Jijun Liu, Brian A. Jonas, Aaron D. Schimmer, Steven Grant, Amer M. Zeidan, Gerhard C. Hildebrandt, Christopher H. Lowrey, Ryan J. Mattison, Neil Palmisiano, Amandeep Salhotra, Dimitrios Tzachanis, Maria R. Baer, Tara L. Lin, Prapti Patel, Helen Chen, Walter M. Stadler, Olatoyosi Odenike, Richard A. Larson, Thomas F. Gajewski, Christopher S. Hourigan, Wendy Stock, Hongtao Liu
Veröffentlicht in Blood Advances (2025-05-01)